Conference Proceeding

Stem cells: Journey towards clinical translation

Dr. Basan Gowda S Kurkalli,
Nitte University Center for Stem Cell Research & Regenerative Medicine, India

Mesenchymal stem cells (MSCs) are a major stem cells source for cellular therapy, used in clinical applications for almost a decade.

Dr. Basan Gowda S Kurkalli served as Senior Scientist at GIOSTAR in October, 2015 (Global Institute For Stem Cell Therapy and Research), Ahmedabad, Gujarat before joining Amrita Center for Nanoscience and Molecular Medicine (ACNS & MM) as Clinical Assistant/Associate Professor in November 2011. He received his doctorate degree in Faculty of Medicine from Hebrew University Jerusalem, Israel, MSC in Zoology from Annamalai University Chidambaram, Tamilnadu and BSc in Zoology from Karnataka University Dharwar, Karnataka State. He served three years as a postdoctoral fellow in the department of bone marrow transplantation, Hadassah/Hebrew University Hospital, Jerusalem, Israel. Prior to joining ACNS & MM he served as Independent Research Scientist/Investigator-in-Charge for a period of 4 years at Cognate Bioservices Ltd., Tel Aviv, Israel, as a part of Cognate Bioservices, Inc. USA. He has 2 national, 11 international research articles and 5 issued international patents and one chapter in a book.Currently he is Professor at Nitte University Center for Stem Cell Research & Regenerative Medicine, India.

Mesenchymal stem cells (MSCs) are a major stem cells source for cellular therapy, used in clinical applications for almost a decade. The “gold rush” to use MSCs in clinical trialsis because they possess self-renewal ability, multilineage differentiation, immunomodulaory properties; easy isolation, ex-vivoexpansion in-vitro. Miniaturized incubator for transportation of sample biopsy would promote in maintaining cellular viability. Adult sources of MSCs: stroma of bone-marrow, adipose /dental tissue and peripheral blood.Currently, there are more than 400 registered clinical trials aimed at evaluating the potential of MSC-based cell therapy. Extensive ex-vivoexpansion of MSCs are prone to lose their therapeutic potential because of changes in cellular organization. Bone-marrow MSCs exert strong therapeutic effect in treating bone disorders, neurological disorders viz., Multiple Sclerosis, Encephalomyelitis, Amyotrophic Lateral Sclerosis, Motor Neuron diseases, Progressive Supranuclear Palsy, Parkinsons, spinal injury. Dental pulp and follicle tissue derived MSCs have osteoconductive, osteoinductive potential in pulp regeneration. Intravenous injection of MSCs has shown to effectively suppress induction of peripheral immunomodulation. Microenvironments play a key role in lineage specification; rigid matrices that mimic collagenous bone are osteogenic in nature. The combination of MSCs derived from bone-marrow, adipose and dental tissue with demineralized/mineralized, bone/teeth matrix finds its application in induction of osteo-hematopoietic microenvironment in aplastic anemia, repairing bone, cartilage defects and dental tissue regeneration. MSCs are also novel platform in gene therapy; where they are exogenously regulated to express desired therapeutic protein for a variety of diseases viz., cancer and skeletal defects.

Published: 28 April 2017